

ACTIVITIES REPORT FOR THE QUARTER ENDED 31 MARCH 2026

HIGHLIGHTS

- Deployment of an additional 500 3DICOM MD® licences to Provider Network Solutions (PNS)
- Payment of USD\$500,000 (~AUD\$700,000) subsequent to Quarter end by PNS as per Binding Enterprise Agreement.
- Commenced discussions with PNS regarding expansion and renewal of licensing arrangements
- Successful go-live and full deployment of 3DICOM™ Patient at Life Radiology, replacing CD-ROM distribution with digital imaging delivery
- Execution of Miami-Dade County Public Schools (M-DCPS) agreement, expanding 3DICOM™ EDU into the third largest U.S. public education system
- Signing of Memorandum of Understanding with Florida International University (FIU) to pilot 3DICOM™ across academic, clinical and research environments
- FDA 510(k) clearance achieved for 3DICOM MD® Cloud platform and participation in U.S. ONC interoperability consultation, strengthening regulatory positioning and alignment with future healthcare standards

The March 2026 Quarter marked a period of consolidation and expansion for Singular Health Group Limited (ASX: SHG) (“Singular Health”), with key milestones achieved across commercial deployment, education partnerships, regulatory engagement, and governance maturity.

Singular Health Managing Director & CEO, Denning Chong stated:

“The March quarter represented a period of strong execution for Singular Health.

As we move into the next two quarters, we are focused on a number of key milestones, including finalising agreements with a U.S. health plan, further demonstrating outcomes from our PNS deployment, and progressing potential expansion and renewal opportunities.”

Building on prior technical and commercial progress, Singular Health successfully transitioned pilot programs into live clinical deployments, expanded its presence within the U.S. education sector, and strengthened its position within emerging regulatory and interoperability frameworks. These developments continue to reinforce Singular Health’s strategy of delivering scalable, interoperable imaging solutions across clinical, educational, and enterprise environments.

PNS Contract ongoing success

Singular Health’s commercial agreement with PNS as per the Binding Enterprise Agreement previously announced on ASX on 19 June 2025 in the United States continues to progress well.

During the Quarter, Singular Health deployed as per the agreed schedule 500 3DICOM MD® licences to PNS’s Primary Care Provider (PCP) network.

The expanded deployment of now 750 3DICOM MD® licenses provide a broader data set across PNS’s network, supporting ongoing evaluation of clinical and economic outcomes associated with the reduction of duplicate imaging.

For personal use only

Preliminary results continue to demonstrate success, including:

- (a) enhanced interoperability across participating providers;
- (b) measurable reductions in unnecessary imaging utilisation and costs; and
- (c) attractive return on investment for PNS.

PNS estimates duplicate imaging costs of approximately US\$35 per member per month across its network of approximately 4.2 million members.

Provider Network Solutions Founder and CEO, Dr. Pelayo commented:

“We view a savings rate of 3%–5% of the US\$35 per member per month of duplicate imaging costs as material savings, and we are currently exceeding all our expectations. This validates our belief in the strong future for the 3DICOM™ platform and its delivery of material reductions in duplicate imaging costs and enhanced efficiencies and interoperability across our network. Based on the results we are seeing, the 3DICOM™ platform is well positioned to attract broader interest from more U.S. healthcare plans as outcomes from our usage are utilised.”

Singular Health has received payment of USD\$500,000 from PNS for licensing fees (refer ASX announcement 22 April 2026), in accordance with the Binding Enterprise Agreement, and have commenced discussions regarding a potential expansion of the deployment, and renewal of licensing arrangements, which is anticipated in late Q3 of CY2026.

Meanwhile, Singular Health and PNS continue to jointly market the 3DICOM™ platform to U.S. health plans, PNS’s affiliate network and joint venture partners nationwide in the U.S.

Life Radiology Deployment and U.S. Clinical Rollout

Following the successful technical integration completed in the prior quarter, Singular Health achieved full go-live of its 3DICOM™ Patient solution at Life Radiology’s Miami clinic during March 2026. The deployment included a stable and secure integration with the clinic’s PACS environment, enabling seamless retrieval and sharing of imaging data through the 3DICOM™ Gateway, and transitioned the method of delivery of images from the use CD-ROM’s to a fully digital, cloud-enabled delivery model.

Clinical and administrative staff are now using the 3DICOM™ Gateway to retrieve radiological images, including CT, MRI, PET, X-ray, and mammography, along with associated reports, and securely distribute them to patients and referring physicians.

Patients receive imaging directly on their mobile devices, with the ability to view scans in both 2D and 3D, and are able to store, manage, and share their records at any time.

Initial feedback has been highly positive from both staff and patients, with strong uptake recorded following go-live. The success of the deployment has led to discussions regarding potential expansion across additional affiliated clinics in other U.S. states, representing a pathway to broader commercial rollout.




Figure 1.3DICOM™ solution successfully deployed at the Life Radiology clinic in Miami (FL).

For personal use only

M-DCPS Education Pilot Deployment

During the Quarter, Singular Health executed a formal agreement for a pilot program with Miami-Dade County Public Schools (“M-DCPS”), the third largest school district in the United States, to deploy its 3DICOM™ EDU platform across the district’s Career and Technical Education network.

The paid pilot, aligned to the 2025–2026 academic year, provides browser-based access to immersive, clinical-grade 3D medical imaging, supporting Health Science, Allied Health, and STEM pathways. Initial deployment is targeted across five M-DCPS Technical Colleges, with access provisioned for up to 150 students and instructors, and designed to integrate seamlessly into existing curriculum delivery.

The program includes platform provisioning, onboarding, instructor training, and ongoing support, as well as analytics and reporting to measure engagement and program effectiveness. The pilot will evaluate student comprehension, instructor adoption, and scalability, with outcomes expected to support potential expansion across additional campuses and programs.

Rene Mantilla, Assistant Superintendent, Office of Postsecondary Career and Technical Education states:

“M-DCPS provides post-secondary students with the cutting-edge tools necessary to succeed in a digital healthcare landscape. This partnership reinforces our mission to deliver high-quality, career-aligned training that prepares our graduates for immediate success in the workforce.”

Memorandum of Understanding with Florida International University

During the Quarter, Singular Health entered into a Memorandum of Understanding (“MoU”) with Florida International University (“FIU”), establishing a framework to pilot the Company’s 3DICOM™ platform across FIU’s Academic Health Sciences Colleges.

The program will assess the application of 3DICOM™ across medical education, clinical workflows, and research environments. Deployment will include 3DICOM™ EDU, 3DICOM MD®, 3DICOM Patient, and 3DICOM™ Repository solutions, supporting radiology training, clinical collaboration, and secure data sharing across FIU and affiliated healthcare organisations and training hospitals.

Strategically, the engagement provides a pathway to validate the platform within a leading academic institution and supports broader U.S. market expansion.

Singular Health has also progressed the initiative in respect of the multi-million US dollar Project Request to the Florida House of Representatives in collaboration with Florida International University (FIU).

This project proposes the creation of a statewide imaging repository for Florida’s Medicaid program. The Company continues to view this prospect positively. Singular Health expects a decision by Q3 calendar year 2026.

Regulatory and Standards Advancement – FDA Clearance and ONC Engagement

During the Quarter, Singular Health achieved a significant regulatory milestone with FDA 510(k) clearance for its 3DICOM MD® Cloud platform, granted in January 2026 within 40 days of submission (refer ASX announcement 13 January 2026). This rapid approval reflects the strength of Singular Health’s regulatory preparation and validates the robustness of its software platform.

The cloud-based solution builds on the existing FDA-cleared desktop viewer and expands support to additional imaging modalities, including X-ray and ultrasound alongside CT, MRI, and PET, significantly broadening clinical applicability across a wider range of care settings.

The transition to a browser-based deployment model removes the need for specialised hardware or complex installations, enabling faster rollout and improved accessibility across distributed healthcare environments.

Crucially, this expands the range of reducing duplicate image requests across more different modalities.

In parallel, Singular Health participated in the U.S. Department of Health and Human Services Office of the National Coordinator for Health Information Technology (“ONC”) Request for Information on diagnostic

For personal use only

imaging interoperability. Singular Health provided policy and technical input based on real-world deployment experience, addressing systemic challenges including PACS fragmentation, limited integration with electronic health records, and inefficiencies contributing to duplicate imaging and increased healthcare costs.

Singular Health's submission positioned 3DICOM™ as a practical, vendor-neutral solution aligned with emerging interoperability standards and future certification frameworks. This engagement supports Singular Health's strategy to contribute to regulatory development while ensuring alignment with evolving U.S. healthcare infrastructure requirements. It ensures that Singular Health is positioned to be a noted industry player and provide input and influence to the criterias for any government initiated project.

Successful Outcome of Independent Information Security Risk Assessment

During the Quarter, Singular Health completed a voluntary, self initiated independent information security threat and risk assessment conducted by Shimazaki Sentinel. The assessment confirmed that Singular Health maintains a strong governance and control framework aligned with international standards, including an ISO-aligned risk management framework, incident response capability, and cloud-based disaster recovery environment.

Importantly, the review identified no evidence of active compromise, and no critical or high risk issues within Singular Health's systems, validating the effectiveness of current controls.

The assessment provided a structured roadmap for continued improvement, including enhanced testing, expanded access controls, and the introduction of proactive monitoring and threat intelligence as the Company scales. Singular Health has committed to implementing all recommendations in a disciplined and prioritised manner, while progressing ISO scope extension and insurance alignment to support U.S. expansion.

Investor Relations and Market Engagement

During the Quarter, Singular Health continued to engage actively with the investment community. Singular Health was featured in an article within Australian Financial Review highlighting emerging small-cap opportunities, recognising Singular Health's role in addressing inefficiencies in the U.S. medical imaging market.

Business Activities Expenditure

Singular Health has submitted its R&D Tax Incentive claim for the financial year, with an estimated refund of approximately \$471,540, subject to ATO assessment and timing of receipt.

In accordance with ASX Listing Rule 4.7C.1, direct operating activities expenditure for the Quarter was \$1,320,000, comprising of:

- research and development expenses of \$266,000,
- product manufacturing and operating costs of \$57,000,
- advertising and marketing costs of \$52,000,
- staff costs of \$701,000, and
- administration and corporate costs of \$324,000,

During the Quarter, the Singular Health received \$270,000 via the exercise of unlisted options.

All other operating expenses tracked in line with forecasted budget with our direct operating expenses for the Quarter being less than the previous quarter.

In accordance with ASX Listing Rule 4.7C.3, payments to related parties of the entity and their associates during the Quarter amounted to \$129,000. Further details are disclosed in the accompanying Appendix 4C at item 6.1.

For personal use only

The cash burn for the Quarter, noting the above, remains in line with and better than budgeted forecasts .

As with previous quarters, there remains no anticipated material increase in quarterly cash outflows prior to material revenues being achieved in 2026.

Cash at bank at the end of the Quarter was \$10,015,000 without accounting for the post quarter payment by PNS of USD\$500,000 (~AUD\$700,000), and an expected R & D refund of \$471,540.

With close to 2 years of available cash runway, Singular Health has a strong financial foundation to enable it to crystallise multiple, material opportunities.

Activities Subsequent to Period End

Subsequent to the end of the Quarter, Singular Health received a payment of USD\$500,000 from PNS. This reinforces PNS endorsement of the 3DICOM™ solution, successful return on investment for PNS and confirms its strong relationship with Singular Health.

Further, Singular Health formally entered the national phase of its patent application and commencing filings across key international jurisdictions. This marks a significant step in securing global protection for MFTP, a core technology underpinning the 3DICOM™ ecosystem and enabling secure, interoperable transfer of medical imaging data across disparate systems.

In addition, the Company's Chief Commercial Officer attended the Health AI Summit in Anaheim, California (April 8–9, 2026), a leading industry forum focused on the real-world deployment of artificial intelligence in healthcare. The event brought together key stakeholders across imaging, clinical AI, and predictive analytics, reinforcing the industry shift toward workflow-integrated solutions that deliver actionable clinical outcomes. Insights from the summit further validated radiology and medical imaging as a primary entry point for scalable AI adoption, alongside increasing emphasis on governance, compliance, and measurable impact.

Outlook

The Company expects continued strong progress across its U.S. initiatives.

Critically, the Company continues to progress advanced-stage commercial discussions with a U.S. health plan and remains confident in executing a contract in the near term. While timing has been extended beyond initial expectations due to seasonal factors, changes in the customer's executive personnel, and the longer decision-making cycles typical of large healthcare organisations, engagement remains active, positive and realistically achievable.

Singular Health believes this engagement sets the scene for a scalable deployment pipeline throughout U.S, via the health plan's broader network.

Similarly, this will solidify contract discussions with other payers within the PNS network and joint venture network nationwide.

Singular Health is highly confident in the strategic significance of this opportunity and its ability to deliver long-term commercial value to payers on a scaleable basis nationally in the U.S. and internationally.

Authorised for ASX release by the Board of Directors.

Ends

For further information contact:

Denning Chong
Managing Director & CEO
support@singular.health
1300 167 795

Paul Berson
Investor Relations
paul@corporatetorytime.com
+61 421 647 445

For personal use only

About Singular Health

Singular Health is a an ASX-listed (ASX: SHG) medical technology company on a mission to create a seamless and integrated healthcare ecosystem where the full value of medical imaging records is unlocked, enabling universal access and promoting interoperability to maximise patient outcomes.

Singular Health's 3DICOM™ software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3DICOM™ MD® is cleared for diagnostic use in the United States.

To learn more, visit <https://singular.health> and <https://investors.singular.health/>

For personal use only

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Singular Health Group Limited

ABN

58 639 242 765

Quarter ended ("current quarter")

31 March 2026

	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	39	75
1.2 Payments for		
(a) research and development	(266)	(664)
(b) product manufacturing and operating costs	(57)	(192)
(c) advertising, marketing and investor relations	(52)	(431)
(d) leased assets	-	-
(e) staff costs	(701)	(2,338)
(f) administration and corporate costs	(324)	(1,125)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	41	255
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other	-	-
1.9 Net cash from / (used in) operating activities	(1,320)	(4,420)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	(10)
(b) businesses	-	-
(c) property, plant and equipment	-	(115)
(d) investments	-	-
(e) intellectual property	-	-

	Current quarter \$A'000	Year to date (9 months) \$A'000
(f) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) entities	16	41
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-
(f) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other	-	-
2.6 Net cash from / (used in) investing activities	16	(84)
3. Cash flows from financing activities		
3.1 Proceeds from issues/unissued of equity securities (excluding convertible debt securities)	-	150
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	270	750
3.4 Transaction costs related to issues of equity securities or convertible debt securities	-	(52)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other – lease payments	(5)	(5)
3.10 Net cash from / (used in) financing activities	265	843
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	11,057	13,679
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,320)	(4,420)

For personal use only

Quarterly cash flow report for entities subject to Listing Rule 4.7B

		Current quarter \$A'000	Year to date (9 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	16	(84)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	265	843
4.5	Effect of movement in exchange rates on cash held	(3)	(3)
4.6	Cash and cash equivalents at end of period	10,015	10,015

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,010	752
5.2	Call deposits	9,000	10,300
5.3	Bank overdrafts	-	-
5.4	Other (Bank Guarantee)	5	5
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	10,015	11,057

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	129
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	
	- Aggregate amount salary paid to Managing Director (\$70), and Non-Executive Director fees of (\$59k).	

7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	-	

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,320)
8.2 Cash and cash equivalents at quarter end (item 4.6)	10,015
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.4 + item 8.5)0	10,015
8.5 Estimated quarters of funding available (item 8.6 divided by item 8.3)	7.59
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

28 April 2026

Date:

The Board of Directors

Authorised by:
 (Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.